PAUL HOWARD is a senior fellow at the Manhattan Institute and director of health policy. Howard was part of the health care policy advisory group for Mitt Romney’s 2012 presidential campaign, has testified twice before Congress, and serves on a panel of judges for Celgene’s Innovation Impact Awards. He is a contributor to the Forbes blog the “Apothecary,” for which he writes about health care policy and entitlement reform, and is a regular columnist for the Morning Consult.
New medicines in the pipeline can extend lives, save money, and even help prevent disease before symptoms appear – if we don’t discourage their innovators and investors by trying to lower drug prices artificially. Unlocking Precision Medicine explores the environment necessary for creation of these health care game-changers, and explains how the marketplace can effectively make them more affordable to all without killing the golden goose.